Tags

Type your tag names separated by a space and hit enter

Genome editing with the CRISPR-Cas system: an art, ethics and global regulatory perspective.
Plant Biotechnol J. 2020 08; 18(8):1651-1669.PB

Abstract

Over the last three decades, the development of new genome editing techniques, such as ODM, TALENs, ZFNs and the CRISPR-Cas system, has led to significant progress in the field of plant and animal breeding. The CRISPR-Cas system is the most versatile genome editing tool discovered in the history of molecular biology because it can be used to alter diverse genomes (e.g. genomes from both plants and animals) including human genomes with unprecedented ease, accuracy and high efficiency. The recent development and scope of CRISPR-Cas system have raised new regulatory challenges around the world due to moral, ethical, safety and technical concerns associated with its applications in pre-clinical and clinical research, biomedicine and agriculture. Here, we review the art, applications and potential risks of CRISPR-Cas system in genome editing. We also highlight the patent and ethical issues of this technology along with regulatory frameworks established by various nations to regulate CRISPR-Cas-modified organisms/products.

Authors+Show Affiliations

National Key Laboratory of Crop Genetic Improvement, Huazhong Agricultural University, Wuhan, China. College of Public Administration, Huazhong Agricultural University, Wuhan, China.National Key Laboratory of Crop Genetic Improvement, Huazhong Agricultural University, Wuhan, China.National Key Laboratory of Crop Genetic Improvement, Huazhong Agricultural University, Wuhan, China.National Key Laboratory of Crop Genetic Improvement, Huazhong Agricultural University, Wuhan, China.Key Laboratory of Agricultural Animal Genetics, Breeding and Reproduction, Ministry of Education, Wuhan, China.Key Laboratory of Agricultural Animal Genetics, Breeding and Reproduction, Ministry of Education, Wuhan, China.Key Laboratory of Horticultural Plant Biology, Ministry of Education, College of Horticulture and Forestry Sciences, Huazhong Agricultural University, Wuhan, China.College of Public Administration, Huazhong Agricultural University, Wuhan, China.National Key Laboratory of Crop Genetic Improvement, Huazhong Agricultural University, Wuhan, China.Hubei Key Laboratory of Plant Pathology, College of Plant Sciences and Technology, Huazhong Agricultural University, Wuhan, China.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

32271968

Citation

Zhang, Debin, et al. "Genome Editing With the CRISPR-Cas System: an Art, Ethics and Global Regulatory Perspective." Plant Biotechnology Journal, vol. 18, no. 8, 2020, pp. 1651-1669.
Zhang D, Hussain A, Manghwar H, et al. Genome editing with the CRISPR-Cas system: an art, ethics and global regulatory perspective. Plant Biotechnol J. 2020;18(8):1651-1669.
Zhang, D., Hussain, A., Manghwar, H., Xie, K., Xie, S., Zhao, S., Larkin, R. M., Qing, P., Jin, S., & Ding, F. (2020). Genome editing with the CRISPR-Cas system: an art, ethics and global regulatory perspective. Plant Biotechnology Journal, 18(8), 1651-1669. https://doi.org/10.1111/pbi.13383
Zhang D, et al. Genome Editing With the CRISPR-Cas System: an Art, Ethics and Global Regulatory Perspective. Plant Biotechnol J. 2020;18(8):1651-1669. PubMed PMID: 32271968.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Genome editing with the CRISPR-Cas system: an art, ethics and global regulatory perspective. AU - Zhang,Debin, AU - Hussain,Amjad, AU - Manghwar,Hakim, AU - Xie,Kabin, AU - Xie,Shengsong, AU - Zhao,Shuhong, AU - Larkin,Robert M, AU - Qing,Ping, AU - Jin,Shuangxia, AU - Ding,Fang, Y1 - 2020/04/30/ PY - 2019/09/20/received PY - 2020/02/22/revised PY - 2020/03/19/accepted PY - 2020/4/10/pubmed PY - 2020/11/3/medline PY - 2020/4/10/entrez KW - CRISPR-Cas system KW - ethics KW - genome editing KW - regulations KW - risks SP - 1651 EP - 1669 JF - Plant biotechnology journal JO - Plant Biotechnol J VL - 18 IS - 8 N2 - Over the last three decades, the development of new genome editing techniques, such as ODM, TALENs, ZFNs and the CRISPR-Cas system, has led to significant progress in the field of plant and animal breeding. The CRISPR-Cas system is the most versatile genome editing tool discovered in the history of molecular biology because it can be used to alter diverse genomes (e.g. genomes from both plants and animals) including human genomes with unprecedented ease, accuracy and high efficiency. The recent development and scope of CRISPR-Cas system have raised new regulatory challenges around the world due to moral, ethical, safety and technical concerns associated with its applications in pre-clinical and clinical research, biomedicine and agriculture. Here, we review the art, applications and potential risks of CRISPR-Cas system in genome editing. We also highlight the patent and ethical issues of this technology along with regulatory frameworks established by various nations to regulate CRISPR-Cas-modified organisms/products. SN - 1467-7652 UR - https://www.unboundmedicine.com/medline/citation/32271968/Genome_editing_with_the_CRISPR_Cas_system:_an_art_ethics_and_global_regulatory_perspective_ DB - PRIME DP - Unbound Medicine ER -